Targeted GATA3 knockdown in activated T cells via pulmonary siRNA delivery as novel therapy for allergic asthma.

[1]  Aqeel Ahmad,et al.  The role of the multifunctional antimicrobial peptide melittin in gene delivery. , 2021, Drug discovery today.

[2]  O. Merkel,et al.  T-cell targeted pulmonary siRNA delivery for the treatment of asthma. , 2020, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[3]  R. Heermann,et al.  Coming in and Finding Out: Blending Receptor‐Targeted Delivery and Efficient Endosomal Escape in a Novel Bio‐Responsive siRNA Delivery System for Gene Knockdown in Pulmonary T Cells , 2019, Advanced therapeutics.

[4]  O. Merkel,et al.  Pulmonary delivery of siRNA as a novel treatment for lung diseases. , 2019, Therapeutic delivery.

[5]  Yuran Xie,et al.  Evaluating the Regulation of Cytokine Levels After siRNA Treatment in Antigen-Specific Target Cell Populations via Intracellular Staining. , 2019, Methods in molecular biology.

[6]  Sheridan M. Hoy.  Patisiran: First Global Approval , 2018, Drugs.

[7]  D. Jonigk,et al.  Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices , 2018, Journal of visualized experiments : JoVE.

[8]  A. Markham,et al.  Benralizumab: First Global Approval , 2018, Drugs.

[9]  P. Olinga,et al.  siRNA-Mediated RNA Interference in Precision-Cut Tissue Slices Prepared from Mouse Lung and Kidney , 2017, The AAPS Journal.

[10]  M. Niehof,et al.  RNA isolation from precision-cut lung slices (PCLS) from different species , 2017, BMC Research Notes.

[11]  A. Moszczynska,et al.  Targeted Delivery of siRNA to Transferrin Receptor Overexpressing Tumor Cells via Peptide Modified Polyethylenimine , 2016, Molecules.

[12]  G. Canonica,et al.  The role of interleukin 5 in asthma , 2016, Expert review of clinical immunology.

[13]  A. Thakur,et al.  Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[14]  G. Canonica,et al.  Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs , 2016, Current opinion in allergy and clinical immunology.

[15]  Julia C. Engelmann,et al.  siPools: highly complex but accurately defined siRNA pools eliminate off-target effects , 2014, Nucleic acids research.

[16]  C. Caruso-Neves,et al.  IL-4: an important cytokine in determining the fate of T cells , 2014, Biophysical Reviews.

[17]  J. Corren.  Role of Interleukin-13 in Asthma , 2013, Current Allergy and Asthma Reports.

[18]  I. Aoki,et al.  Pathology of asthma , 2013, Front. Microbiol..

[19]  H. Chan,et al.  Liposomal formulations for inhalation. , 2013, Therapeutic delivery.

[20]  N. H. Kim,et al.  Tracking and treating activated T cells. , 2013, Journal of drug delivery science and technology.

[21]  A. Vatrella,et al.  The potential of biologics for the treatment of asthma , 2012, Nature Reviews Drug Discovery.

[22]  T. Kissel,et al.  Nonviral pulmonary delivery of siRNA. , 2012, Accounts of chemical research.

[23]  S. Holgate.  Innate and adaptive immune responses in asthma , 2012, Nature Medicine.

[24]  T. Kissel,et al.  Comparative in vivo study of poly(ethylene imine)/siRNA complexes for pulmonary delivery in mice. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[25]  R. Lockey,et al.  Interleukin-13 Signaling and Its Role in Asthma , 2011, The World Allergy Organization journal.

[26]  E. Campbell,et al.  Metabolic Shifts in Immunity and Inflammation , 2010, The Journal of Immunology.

[27]  Anja Schindler,et al.  A Direct Phenotypic Comparison of siRNA Pools and Multiple Individual Duplexes in a Functional Assay , 2009, PloS one.

[28]  K. Takatsu,et al.  IL-5- and eosinophil-mediated inflammation: from discovery to therapy. , 2009, International immunology.

[29]  G. Anderson,et al.  Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease , 2008, The Lancet.

[30]  F. Finkelman,et al.  Distinct roles for IL-13 and IL-4 via IL-13 receptor α1 and the type II IL-4 receptor in asthma pathogenesis , 2008, Proceedings of the National Academy of Sciences.

[31]  W. Henke,et al.  Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme. , 2008, The Journal of allergy and clinical immunology.

[32]  D. Curran‐Everett,et al.  Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. , 2007, The Journal of allergy and clinical immunology.

[33]  I. Adcock,et al.  Update on glucocorticoid action and resistance. , 2006, The Journal of allergy and clinical immunology.

[34]  Dave P. Miller,et al.  High Prevalence of Skin Test Positivity in Severe or Difficult-to-Treat Asthma , 2006, The Journal of asthma : official journal of the Association for the Care of Asthma.

[35]  W. Paul,et al.  GATA-3 promotes Th2 responses through three different mechanisms: induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors , 2006, Cell Research.

[36]  S. Mocellin,et al.  RNA interference: learning gene knock-down from cell physiology , 2004, Journal of Translational Medicine.

[37]  M. Kubo,et al.  The IL-4 production capability of different strains of naive CD4(+) T cells controls the direction of the T(h) cell response. , 2002, International immunology.

[38]  P. Bucher,et al.  DNA Binding Specificity of Different STAT Proteins , 2001, The Journal of Biological Chemistry.

[39]  A. Dautry‐Varsat,et al.  Interleukin 2 receptors and detergent-resistant membrane domains define a clathrin-independent endocytic pathway. , 2001, Molecular cell.

[40]  Shu-Hsia Chen,et al.  Gr-1+ Myeloid Cells Derived from Tumor-Bearing Mice Inhibit Primary T Cell Activation Induced Through CD3/CD28 Costimulation1 , 2000, The Journal of Immunology.

[41]  A. Ray,et al.  Th2 cells and GATA-3 in asthma: new insights into the regulation of airway inflammation. , 1999, The Journal of clinical investigation.

[42]  K. Heider,et al.  Polycation‐based DNA complexes for tumor‐targeted gene delivery in vivo , 1999, The journal of gene medicine.

[43]  J. D. de Vries.  The role of IL-13 and its receptor in allergy and inflammatory responses. , 1998, The Journal of allergy and clinical immunology.

[44]  J. Bluestone,et al.  CD28/B7 system of T cell costimulation. , 1996, Annual review of immunology.